<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>RATIONALE: Catecholaminergic polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e>) is caused by mutations in cardiac <z:chebi fb="0" ids="8925">ryanodine</z:chebi> receptor (RyR2) or calsequestrin (Casq2) genes </plain></SENT>
<SENT sid="1" pm="."><plain>Sinoatrial node dysfunction associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> may increase the risk for <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> (VA) </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To test the hypothesis that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> is suppressed by supraventricular overdrive stimulation </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> mouse models (Casq2(-/-) and RyR2(R4496C/+) mice), the effect of increasing sinus heart rate was tested by pretreatment with <z:chebi fb="28" ids="16684">atropine</z:chebi> and by atrial overdrive pacing </plain></SENT>
<SENT sid="4" pm="."><plain>Increasing intrinsic sinus rate with <z:chebi fb="28" ids="16684">atropine</z:chebi> before <z:chebi fb="2" ids="33567">catecholamine</z:chebi> challenge suppressed <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> in 86% of Casq2(-/-) mice (6/7) and significantly reduced the VA score (<z:chebi fb="28" ids="16684">atropine</z:chebi>: 0.6±0.2 versus vehicle: 1.7±0.3; P&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Atrial overdrive pacing completely prevented VA in 16 of 19 (84%) Casq2(-/-) and in 7 of 8 (88%) RyR2(R4496C/+) mice and significantly reduced <z:mp ids='MP_0009732'>ventricular premature beats</z:mp> in both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> models (P&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Rapid pacing also prevented spontaneous calcium waves and triggered beats in isolated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> myocytes </plain></SENT>
<SENT sid="7" pm="."><plain>In humans, heart rate dependence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> was evaluated by screening a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> patient registry for antiarrhythmic drug-naïve individuals that reached &gt;85% of their maximum-predicted heart rate during exercise testing </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 18 CPVT patients who fulfilled the inclusion criteria exhibited VA before reaching 87% of maximum heart rate </plain></SENT>
<SENT sid="9" pm="."><plain>In 6 CPVT patients (33%), VA were paradoxically suppressed as sinus heart rates increased further with continued exercise </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Accelerated supraventricular rates suppress VAs in 2 CPVT mouse models and in a subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Hypothetically, atrial overdrive pacing may be a therapy for preventing exercise-induced <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> in treatment-refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> patients </plain></SENT>
</text></document>